Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Alexander X. Lozano, Aadel A. Chaudhuri, Aishwarya Nene, et al.
Nature Medicine (2022) Vol. 28, Iss. 2, pp. 353-362
Open Access | Times Cited: 204

Showing 1-25 of 204 citing articles:

Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 459
Immune-related adverse events of immune checkpoint inhibitors: a review
Qinan Yin, Liuyun Wu, Lizhu Han, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 139
T follicular helper cells in cancer
Nicolás Gutiérrez-Melo, Dirk Baumjohann
Trends in cancer (2023) Vol. 9, Iss. 4, pp. 309-325
Open Access | Times Cited: 105
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases
Alice Tison, Soizic Garaud, Laurent Chiche, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 11, pp. 641-656
Closed Access | Times Cited: 103
Immune mechanisms of toxicity from checkpoint inhibitors
S. Jennifer Wang, Stephanie K. Dougan, Michael Dougan
Trends in cancer (2023) Vol. 9, Iss. 7, pp. 543-553
Open Access | Times Cited: 90
Single cell sequencing identifies clonally expanded synovial CD4+ TPH cells expressing GPR56 in rheumatoid arthritis
Alexandra Argyriou, Marc H. Wadsworth, Adrian Lendvai, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 84
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors
Nicolás Gonzalo Núñez, Fiamma Berner, Ekaterina Friebel, et al.
Med (2023) Vol. 4, Iss. 2, pp. 113-129.e7
Open Access | Times Cited: 71
Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions
Chenyue Zhang, Chenxing Zhang, Haiyong Wang
Cancer Letters (2023) Vol. 562, pp. 216182-216182
Closed Access | Times Cited: 56
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma
Zhichao Liu, Yaru Zhang, Ning Ma, et al.
Cancer Cell (2023) Vol. 41, Iss. 11, pp. 1852-1870.e9
Open Access | Times Cited: 55
Clinical and translational attributes of immune-related adverse events
Karijn P.M. Suijkerbuijk, Mick J M van Eijs, Femke van Wijk, et al.
Nature Cancer (2024) Vol. 5, Iss. 4, pp. 557-571
Closed Access | Times Cited: 38
Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics
Gunsagar S. Gulati, Jeremy Philip D’Silva, Yunhe Liu, et al.
Nature Reviews Molecular Cell Biology (2024) Vol. 26, Iss. 1, pp. 11-31
Closed Access | Times Cited: 33
Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Manuel Ramos‐Casals, Antoni Sisó‐Almirall
Annals of Internal Medicine (2024) Vol. 177, Iss. 2, pp. ITC17-ITC32
Closed Access | Times Cited: 23
Pulmonary toxicity of immune checkpoint immunotherapy
Mohammad I. Ghanbar, Karthik Suresh
Journal of Clinical Investigation (2024) Vol. 134, Iss. 2
Open Access | Times Cited: 21
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno
Japanese Journal of Clinical Oncology (2024) Vol. 54, Iss. 9, pp. 949-958
Open Access | Times Cited: 16
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Remo Poto, Teresa Troiani, Gjada Criscuolo, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 67
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
Ramin S. Herati, David A. Knorr, Laura A. Vella, et al.
Nature Immunology (2022) Vol. 23, Iss. 8, pp. 1183-1192
Open Access | Times Cited: 60
Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines
Robin Reschke, Jason W. Shapiro, Jovian Yu, et al.
Cancer Immunology Research (2022) Vol. 10, Iss. 10, pp. 1167-1174
Open Access | Times Cited: 54
Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation
Haonan Li, Qiang Luo, Hu Zhang, et al.
Chemical Society Reviews (2022) Vol. 52, Iss. 1, pp. 47-96
Closed Access | Times Cited: 44
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Ben Sprangers, David E. Leaf, Camillo Porta, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 12, pp. 794-805
Closed Access | Times Cited: 40
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
Shoiab Bukhari, Brian S. Henick, Robert Winchester, et al.
Cell Reports Medicine (2022) Vol. 4, Iss. 1, pp. 100868-100868
Open Access | Times Cited: 40
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
Betul Ibis, Konstantinos Aliazis, Carol Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 39
Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma
Weijie Xue, Kang Qiu, Bingzi Dong, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 38
Computational immunogenomic approaches to predict response to cancer immunotherapies
Venkateswar Addala, Felicity Newell, John V. Pearson, et al.
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 1, pp. 28-46
Open Access | Times Cited: 34
Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis
Iago Pinal-Fernández, Ángela Quintana, José C. Milisenda, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 6, pp. 829-836
Open Access | Times Cited: 33
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium
Talal El Zarif, Amin H. Nassar, Elio Adib, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 21, pp. 3712-3723
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top